2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol | 892142-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol
• 英文别名: 2-[[4-[4-[(3-fluorophenyl)methoxy]-3-methylanilino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy]ethanol
• CAS: 892142-89-1
• 化学式: C₂₁H₂₀FN₅O₃
• 分子量: 409.42
• InChiKey: LOPQEHBTGQRZFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol 、 甲基磺酰氯 在 吡啶 作用下， 反应 1.0h， 生成 2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethyl methanesulfonate
  参考文献：
  名称：

  Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors

  摘要：

  Novel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.035
• 作为产物：
  描述：

  N'-[4-cyano-3-(2-hydroxyethoxy)-1H-pyrazol-5-yl]-N,N-dimethylimidoformamide 、 4-(3-fluoro-benzyloxy)-3-methyl-phenylamine 以to give the title compound as a white solid (2.12 g, 58%)的产率得到2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol
  参考文献：
  名称：

  Pyrazolopyrimidine Compounds as Antitumor Agents

  摘要：

  本发明涉及式(I)的化合物，其中取代基如文本中所定义，用于在温血动物如人体内产生抗增殖作用，该作用单独或部分地通过抑制erbB2受体酪氨酸激酶来产生。

  公开号：

  US20080108613A1

文献信息

• Pyrazolopyrimidine Compounds as Antitumor Agents
  申请人：Barlaam Bernard Christophe

  公开号：US20080108613A1

  公开（公告）日：2008-05-08

  The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  本发明涉及式(I)的化合物，其中取代基如文本中所定义，用于在温血动物如人体内产生抗增殖作用，该作用单独或部分地通过抑制erbB2受体酪氨酸激酶来产生。
• Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
  申请人：AstraZeneca AB

  公开号：US07947676B2

  公开（公告）日：2011-05-24

  The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  本发明涉及式(I)化合物，其中取代基如文本中所定义，用于在温血动物（例如人）中产生抗增殖效应，该效应单独或部分地通过抑制erbB2受体酪氨酸激酶来产生。
• PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUMOR AGENTS
  申请人：AstraZeneca AB

  公开号：EP1838712B1

  公开（公告）日：2011-03-09
• US7947676B2
  申请人：——

  公开号：US7947676B2

  公开（公告）日：2011-05-24
• Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors
  作者：Richard Ducray、Peter Ballard、Bernard C. Barlaam、Mark D. Hickinson、Jason G. Kettle、Donald J. Ogilvie、Catherine B. Trigwell

  DOI：10.1016/j.bmcl.2007.12.035

  日期：2008.2

  Novel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.